Collin Williams

Collin Williams is an accomplished professional with extensive experience in the biotechnology and clinical development sectors. Currently serving as President of Tempus Compass at Tempus AI since 2022, Williams previously founded and led Highline Sciences as CEO until its acquisition by Tempus Labs, Inc. Additional experience includes roles as Executive Clinical Development Consultant at Sutro Biopharma, Inc. and Clinical Development Consultant at Clovis Oncology. Williams also held positions in clinical operations at Gilead Sciences and Quintiles, Inc. Educational qualifications include an MBA from the University of California, Berkeley, Haas School of Business, and a Bachelor of Arts in Biology/Genetics from The University of Kansas.